Loading...
Loading...
ANNX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.9M |
| Gross Profit | -0.9M |
| Operating Expense | 32.7M |
| Operating I/L | -33.6M |
| Other Income/Expense | 4.0M |
| Interest Income | 4.0M |
| Pretax | -29.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -29.6M |
Annexon, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's product candidates, including ANX005, ANX009, ANX007, ANX105, and ANX1502, are in various stages of clinical trials targeting conditions such as guillain-barré syndrome, warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, lupus nephritis, and geographic atrophy. Annexon's focus on developing monoclonal antibodies and oral small molecules demonstrates its commitment to addressing distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration, with the potential to generate revenue through successful commercialization.
